GenomeKey raise Innovate UK funding to drive life-saving next-gen sepsis diagnostic

Our member GenomeKey, has secured an Innovate UK Biomedical Catalyst research award of £950,000 towards faster diagnosis and treatment of sepsis, one of the world’s most deadly diseases. The funding will enable the Bristol-based research and development company to provide rapid bacterial species identification and antimicrobial profiling in the hospital, which will save lives, save money,…

Read More

getUBetter invited to join NHS Innovation Accelerator

Dr. Carey McClellan, CEO of our member company getUBetter, has been invited to join the prestigious NHS Innovation Accelerator (NIA) as a Fellow. NIA was established in 2020 to support exceptional individuals to scale promising innovations across England’s NHS. getUBetter has experienced significant growth over the last 12 months and is now providing its digital self-management…

Read More

Femtech startup LatchAid secures £1m seed funding

Our member LatchAid, an award winning breastfeeding and early parenthood support innovator, has closed its seed funding round with an ultra-competitive £510k Innovate UK Innovation Loan, bringing total investments to £1m, as testament to its ground-breaking technology and user traction. LatchAid was founded by Dr Chen Mao Davies, a R&D specialist who previously worked on the Oscar (Academy Award)…

Read More

FluoretiQ announces the closure of £1.1 million funding round

Our member and University of Bristol spin-out, FluoretiQ, has today announced the completion of a £1.1 million, pre-series A investment. Their pioneering NANOPLEX technology is a 15-minute proprietary diagnostic platform for bacterial infections.   The round was led by early-stage life science investors, Deepbridge Capital LLP, with significant participation from MAINStream, OION, SAIC and existing investors. This…

Read More

FluoretiQ case study: Revolutionising bacterial diagnostics

To help our aspiring entrepreneurs and future SETsquared Bristol members, we showcase member and alumni case studies demonstrating the breadth of tech at SETsquared Bristol and what it takes to achieve success. We had a chat with FluoretiQ Co-founder and CEO, Neciah Dorh… FluoretiQ Key Facts Start date: 2 March 2017 Market sector: Healthcare (Diagnostics) Location:  Bristol Number of employees: 10…

Read More

LatchAid case study: Using tech to support breastfeeding and motherhood

To help our aspiring entrepreneurs and future SETsquared Bristol members, we showcase member and alumni case studies demonstrating the breadth of tech at SETsquared Bristol and what it takes to achieve success. We had a chat with LatchAid Founder and CEO, Dr. Chen Mao Davies… LatchAid Key Facts Start date: July 2018 Market sector: Femtech Location: Bristol Number of employees: 3 Amount…

Read More

GenomeKey case study: Saving lives through early diagnosis of sepsis

To help our aspiring entrepreneurs and future SETsquared Bristol members, we showcase member and alumni case studies demonstrating the breadth of tech at SETsquared Bristol and what it takes to achieve success. We had a chat with GenomeKey CEO, Michael Roberts… GenomeKey Facts Start date:  August 2019 Market sector: Medtech/diagnostics Location: Bristol Number of employees: 9 growing to 12 and beyond Amount…

Read More

Neuronostics reach final of global competition

Neuronostics, a SETsquared Bristol member, is one of four finalists for the Nature Spinoff Prize 2021. The finalists were chosen for their potential to translate world-leading scientific research into products and services that would have lasting impact on society. Neuronostics was co-founded by Professor John Terry and Dr Wessel Woldman in 2018. Since that time,…

Read More

AutonoMe secures investment to expand support to vulnerable people

SETsquared Bristol member, the Bristol-based educational technology developer AutonoMe, has raised over £400k in its latest funding round to further enhance its support for vulnerable people in Education and Social Care settings. The investment, which has been made by City Funds, South East Angels, Bristol Private Equity Club and current shareholders, will help AutonoMe to…

Read More

CARB-X is funding UK-biotech GenomeKey to develop a rapid diagnostic for sepsis, a leading cause of death in hospitals

(BOSTON) – CARB-X is awarding SETsquared Bristol member, GenomeKey (Genomics Labs Ltd.) in Bristol, UK, up to $9.5 million in grant funding to develop an innovative rapid diagnostic for sepsis. The new diagnostic would significantly reduce the time it takes to determine what bacteria are causing an infection and which antibiotics would be most effective…

Read More